SNM Annual Meeting Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     



J Nucl Med. 2008; 49 (Supplement 1):310P
This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Lacoeuille, F.
Right arrow Articles by Le Jeune, J. J.
PubMed
Right arrow Articles by Lacoeuille, F.
Right arrow Articles by Le Jeune, J. J.

Radiopharmaceutical Chemistry: Radiopharmacy

Radiopharmacy Posters

New radiopharmaceutical family for lung perfusion scintigraphy: A safe starch-based alternative to MAA Tc-99m

Franck Lacoeuille1, François Hindré1, Benoit Denizot1, Francis Bouchet2, Olivier Couturier1, Jean Pierre Benoit1, Serge Askienazy3 and Jean Jacques Le Jeune1

1 University of Angers, Inserm U646, Angers, France; 2 Nuclear Medicine, CHU Angers, Angers, France; 3 Cyclopharma, St Beauzire, France

1320

Objectives: A major risk for use of technetium-99m albumin macroaggregates (MAA) is due to potential microbiological contamination of human serum albumin. To avoid such risks we developed and characterized new radiopharmaceutical starch-based microparticles labelled by Tc-99m and evaluated their biodistribution in rodents.

Methods: Particles size, elemental analysis, electron and confocal microscopy were performed at several preparation stages. After evaluation of radiochemical purity, biodistributions were studied on healthy rats by scintigraphic dynamic acquisitions after IV injection (n=3).

Results: Clinically significant characteristics for different ready-to-use kit formulations were compared with the commercially available Tc-99m MAA ones (table). The different starch-based formulations exhibited shorter pulmonary half lives than reference Tc-99m MAA with in vivo performances compatible with clinical use.


Figure 1
In vitro and in vivo characteristics (n=3) of the ready-to-use kit formulations and commercially available Tc-99m MAA.

Conclusions: We developed new starch based Tc-99m labelled microparticles family for lung perfusion scintigraphy with performances similar to widely used albumin macroaggregates without microbiological risks.

Research Support: Industrial research grant (Cyclopharma)





This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Lacoeuille, F.
Right arrow Articles by Le Jeune, J. J.
PubMed
Right arrow Articles by Lacoeuille, F.
Right arrow Articles by Le Jeune, J. J.